Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial

被引:28
|
作者
Juergens, Christine [1 ]
de Villiers, Pierre J. T. [2 ]
Moodley, Keymanthri [2 ]
Jayawardene, Deepthi [3 ]
Jansen, Kathrin U. [3 ]
Scott, Daniel A. [3 ]
Emini, Emilio A. [3 ]
Gruber, William C. [3 ]
Schmoele-Thoma, Beate [1 ]
机构
[1] Pfizer GmbH, Berlin, Germany
[2] Univ Stellenbosch, ZA-7505 Tygerberg, South Africa
[3] Pfizer Inc, Pearl River, NY USA
关键词
13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; adults; elderly; immunogenicity; PCV13; PPSV23; safety; OPSONOPHAGOCYTIC ASSAY; RESPONSES;
D O I
10.4161/hv.27998
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) for adults. The aims were to: identify an age-appropriate PCV13 formulation, i.e., with (n = 309) or without (n = 304) aluminum phosphate (AlPO4); compare the selected PCV13 formulation (n = 309) with 23-valent pneumococcal polysaccharide vaccine (PPSV23; n = 301); and, together with an extension study, assess sequential use of pneumococcal vaccines at 1-year intervals in adults aged >= 65 years (n = 105) not pre-vaccinated with PPSV23. Immune responses were measured by ELISA and opsonophagocytic activity assays 1 month postvaccination. Immunoglobulin G responses elicited by PCV13 with AlPO4 and PCV13 without AlPO4 were similar for the majority, and noninferior for all PCV13 serotypes. PCV13 with AlPO4 was generally more reactogenic, with reactions mainly mild or moderate. Thus, PCV13 with AlPO4 (hereafter PCV13) became the selected formulation. Immune responses to PCV13 were noninferior for all but one serotype and for most PCV13 serotypes superior to PPSV23. Vaccine sequence assessments showed that for PCV13/PPSV23, the initial PCV13 dose generally enhanced responses to a subsequent PPSV23 dose, compared with PPSV23 alone. For PCV13/PCV13, a second dose did not enhance the first dose response when given after 1 year. For PCV13/PPSV23/PCV13, priming with PCV13 (vaccination 1) did not protect against lower responses induced by PPSV23 to subsequent PCV13 (vaccination 3). In conclusion, the pediatric PCV13 formulation with AlPO4 is well tolerated and immunogenic in adults, is generally more immunogenic than PPSV23, and subsequent vaccination with PPSV23 is possible if required.
引用
收藏
页码:1343 / 1353
页数:11
相关论文
共 50 条
  • [31] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and previously immunized adult patients with severe chronic kidney disease
    Ulanova, Marina
    Huska, Brenda
    Desbiens, Angele
    Gaultier, Gabrielle N.
    Domonkos, Victoria
    McCready, William G.
    VACCINE, 2021, 39 (04) : 699 - 710
  • [32] Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine
    Glesby, Marshall J.
    Watson, Wendy
    Brinson, Cynthia
    Greenberg, Richard N.
    Lalezari, Jacob P.
    Skiest, Daniel
    Sundaraiyer, Vani
    Natuk, Robert
    Gurtman, Alejandra
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    JOURNAL OF INFECTIOUS DISEASES, 2015, 212 (01): : 18 - 27
  • [33] Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study
    Lombardi, Francesca
    Belmonti, Simone
    Fabbiani, Massimiliano
    Morandi, Matteo
    Rossetti, Barbara
    Tordini, Giacinta
    Cauda, Roberto
    De Luca, Andrea
    Di Giambenedetto, Simona
    Montagnani, Francesca
    PLOS ONE, 2016, 11 (06):
  • [34] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Bennett, Nancy M.
    Whitney, Cynthia G.
    Moore, Matt
    Pilishvili, Tamara
    Dooling, Kathleen L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (01) : 232 - 235
  • [35] IMMUNOGENICITY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH SPONDYLOARTHRITIS
    Muravyeva, N.
    Belov, B.
    Baranova, M.
    Cherkasova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 854 - 855
  • [36] Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine
    Frenck, Robert, Jr.
    Thompson, Allison
    Yeh, Sylvia H.
    London, Arnold
    Sidhu, Mohinder S.
    Patterson, Scott
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    Gurtman, Alejandra
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (12) : 1086 - 1091
  • [37] THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
    Wu, D. B. C.
    Chang, C. J.
    Chien, L.
    Fang, H. C. H.
    Roberts, C. S.
    VALUE IN HEALTH, 2012, 15 (07) : A602 - A602
  • [38] Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers
    Yeh, Sylvia H.
    Gurtman, Alejandra
    Hurley, David C.
    Block, Stan L.
    Schwartz, Richard H.
    Patterson, Scott
    Jansen, Kathrin U.
    Love, Jack
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    PEDIATRICS, 2010, 126 (03) : E493 - E505
  • [39] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [40] IMMUNOGENICITY AND SAFETY OF 4 DOSES OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOLLOWED BY 1 DOSE OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS AGED ≥2 YEARS: AN OPEN LABEL CLINICAL TRIAL
    Cordonnier, C.
    Ljungman, P.
    Juergens, C.
    Maertens, J.
    Selleslag, D.
    Sundaraiyer, V.
    Clarke, K.
    Gruber, W. C.
    Scott, D. A.
    Schmoele-Thoma, B.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S82 - S83